Antiendothelial cell antibodies in patients with Wegener's granulomatosis

Prevalence and correlation with disease activity and manifestations

Jodi K. Sebastian, Alfred D. Mahr, Sohail S. Ahmed, John H. Stone, Zurina Romay-Penabad, John C. Davis, Gary S. Hoffman, W. Joseph McCune, E. William St. Clair, Ulrich Specks, Robert Spiera, Silvia Pierangeli, Peter A. Merkel

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective. Previous studies in small cohorts of patients with Wegener's granulomatosis (WG) or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have yielded conflicting data regarding the prevalence of antiendothelial cell antibodies (AECA), ranging from 8% to 100%, and the use of AECA as a measure of disease activity. We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA. Methods. Serum from subjects with WG who participated in a clinical therapeutic trial was collected at baseline, when all subjects had active disease. Clinical manifestations and disease activity were documented using the Birmingham Vasculitis Activity Score for WG (BVAS/WG). Serum AECA (IgG) was measured by cyto-ELISA using unfixed human umbilical vein endothelial cells (HUVEC). The AECA positivity cutoff was determined using 71 healthy control samples. Statistical analyses utilized Student's t test, chi-square and Fisher's exact tests, and linear regression. Results. AECA were detected in 34 of 173 (20%) evaluated serum samples. Mean BVAS/WG did not differ between patients with (7.3 ± 3.2) or without AECA (7.0 ± 3.3) (p = 0.58). Among the 34 patients positive for AECA, the antibody titer did not correlate with disease activity (BVAS/WG; r = 0.09, p = 0.60). There were no statistically significant differences in the frequency of major clinical manifestations between patients with or without AECA. Conclusion. AECA, as measured using HUVEC, are not highly prevalent among patients with active WG, are not associated with specific clinical manifestations, and do not correlate with level of disease activity.

Original languageEnglish (US)
Pages (from-to)1027-1031
Number of pages5
JournalJournal of Rheumatology
Volume34
Issue number5
StatePublished - May 2007

Fingerprint

Granulomatosis with Polyangiitis
Vasculitis
Human Umbilical Vein Endothelial Cells
Serum
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
anti-endothelial cell antibody
Chi-Square Distribution
Linear Models
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Students

Keywords

  • Antiendothelial cell antibodies
  • Disease activity measures
  • Wegener's granulomatosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Sebastian, J. K., Mahr, A. D., Ahmed, S. S., Stone, J. H., Romay-Penabad, Z., Davis, J. C., ... Merkel, P. A. (2007). Antiendothelial cell antibodies in patients with Wegener's granulomatosis: Prevalence and correlation with disease activity and manifestations. Journal of Rheumatology, 34(5), 1027-1031.

Antiendothelial cell antibodies in patients with Wegener's granulomatosis : Prevalence and correlation with disease activity and manifestations. / Sebastian, Jodi K.; Mahr, Alfred D.; Ahmed, Sohail S.; Stone, John H.; Romay-Penabad, Zurina; Davis, John C.; Hoffman, Gary S.; McCune, W. Joseph; St. Clair, E. William; Specks, Ulrich; Spiera, Robert; Pierangeli, Silvia; Merkel, Peter A.

In: Journal of Rheumatology, Vol. 34, No. 5, 05.2007, p. 1027-1031.

Research output: Contribution to journalArticle

Sebastian, JK, Mahr, AD, Ahmed, SS, Stone, JH, Romay-Penabad, Z, Davis, JC, Hoffman, GS, McCune, WJ, St. Clair, EW, Specks, U, Spiera, R, Pierangeli, S & Merkel, PA 2007, 'Antiendothelial cell antibodies in patients with Wegener's granulomatosis: Prevalence and correlation with disease activity and manifestations', Journal of Rheumatology, vol. 34, no. 5, pp. 1027-1031.
Sebastian, Jodi K. ; Mahr, Alfred D. ; Ahmed, Sohail S. ; Stone, John H. ; Romay-Penabad, Zurina ; Davis, John C. ; Hoffman, Gary S. ; McCune, W. Joseph ; St. Clair, E. William ; Specks, Ulrich ; Spiera, Robert ; Pierangeli, Silvia ; Merkel, Peter A. / Antiendothelial cell antibodies in patients with Wegener's granulomatosis : Prevalence and correlation with disease activity and manifestations. In: Journal of Rheumatology. 2007 ; Vol. 34, No. 5. pp. 1027-1031.
@article{ffb4259f9dcc40e386ac06e21e9dec12,
title = "Antiendothelial cell antibodies in patients with Wegener's granulomatosis: Prevalence and correlation with disease activity and manifestations",
abstract = "Objective. Previous studies in small cohorts of patients with Wegener's granulomatosis (WG) or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have yielded conflicting data regarding the prevalence of antiendothelial cell antibodies (AECA), ranging from 8{\%} to 100{\%}, and the use of AECA as a measure of disease activity. We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA. Methods. Serum from subjects with WG who participated in a clinical therapeutic trial was collected at baseline, when all subjects had active disease. Clinical manifestations and disease activity were documented using the Birmingham Vasculitis Activity Score for WG (BVAS/WG). Serum AECA (IgG) was measured by cyto-ELISA using unfixed human umbilical vein endothelial cells (HUVEC). The AECA positivity cutoff was determined using 71 healthy control samples. Statistical analyses utilized Student's t test, chi-square and Fisher's exact tests, and linear regression. Results. AECA were detected in 34 of 173 (20{\%}) evaluated serum samples. Mean BVAS/WG did not differ between patients with (7.3 ± 3.2) or without AECA (7.0 ± 3.3) (p = 0.58). Among the 34 patients positive for AECA, the antibody titer did not correlate with disease activity (BVAS/WG; r = 0.09, p = 0.60). There were no statistically significant differences in the frequency of major clinical manifestations between patients with or without AECA. Conclusion. AECA, as measured using HUVEC, are not highly prevalent among patients with active WG, are not associated with specific clinical manifestations, and do not correlate with level of disease activity.",
keywords = "Antiendothelial cell antibodies, Disease activity measures, Wegener's granulomatosis",
author = "Sebastian, {Jodi K.} and Mahr, {Alfred D.} and Ahmed, {Sohail S.} and Stone, {John H.} and Zurina Romay-Penabad and Davis, {John C.} and Hoffman, {Gary S.} and McCune, {W. Joseph} and {St. Clair}, {E. William} and Ulrich Specks and Robert Spiera and Silvia Pierangeli and Merkel, {Peter A.}",
year = "2007",
month = "5",
language = "English (US)",
volume = "34",
pages = "1027--1031",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Antiendothelial cell antibodies in patients with Wegener's granulomatosis

T2 - Prevalence and correlation with disease activity and manifestations

AU - Sebastian, Jodi K.

AU - Mahr, Alfred D.

AU - Ahmed, Sohail S.

AU - Stone, John H.

AU - Romay-Penabad, Zurina

AU - Davis, John C.

AU - Hoffman, Gary S.

AU - McCune, W. Joseph

AU - St. Clair, E. William

AU - Specks, Ulrich

AU - Spiera, Robert

AU - Pierangeli, Silvia

AU - Merkel, Peter A.

PY - 2007/5

Y1 - 2007/5

N2 - Objective. Previous studies in small cohorts of patients with Wegener's granulomatosis (WG) or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have yielded conflicting data regarding the prevalence of antiendothelial cell antibodies (AECA), ranging from 8% to 100%, and the use of AECA as a measure of disease activity. We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA. Methods. Serum from subjects with WG who participated in a clinical therapeutic trial was collected at baseline, when all subjects had active disease. Clinical manifestations and disease activity were documented using the Birmingham Vasculitis Activity Score for WG (BVAS/WG). Serum AECA (IgG) was measured by cyto-ELISA using unfixed human umbilical vein endothelial cells (HUVEC). The AECA positivity cutoff was determined using 71 healthy control samples. Statistical analyses utilized Student's t test, chi-square and Fisher's exact tests, and linear regression. Results. AECA were detected in 34 of 173 (20%) evaluated serum samples. Mean BVAS/WG did not differ between patients with (7.3 ± 3.2) or without AECA (7.0 ± 3.3) (p = 0.58). Among the 34 patients positive for AECA, the antibody titer did not correlate with disease activity (BVAS/WG; r = 0.09, p = 0.60). There were no statistically significant differences in the frequency of major clinical manifestations between patients with or without AECA. Conclusion. AECA, as measured using HUVEC, are not highly prevalent among patients with active WG, are not associated with specific clinical manifestations, and do not correlate with level of disease activity.

AB - Objective. Previous studies in small cohorts of patients with Wegener's granulomatosis (WG) or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have yielded conflicting data regarding the prevalence of antiendothelial cell antibodies (AECA), ranging from 8% to 100%, and the use of AECA as a measure of disease activity. We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA. Methods. Serum from subjects with WG who participated in a clinical therapeutic trial was collected at baseline, when all subjects had active disease. Clinical manifestations and disease activity were documented using the Birmingham Vasculitis Activity Score for WG (BVAS/WG). Serum AECA (IgG) was measured by cyto-ELISA using unfixed human umbilical vein endothelial cells (HUVEC). The AECA positivity cutoff was determined using 71 healthy control samples. Statistical analyses utilized Student's t test, chi-square and Fisher's exact tests, and linear regression. Results. AECA were detected in 34 of 173 (20%) evaluated serum samples. Mean BVAS/WG did not differ between patients with (7.3 ± 3.2) or without AECA (7.0 ± 3.3) (p = 0.58). Among the 34 patients positive for AECA, the antibody titer did not correlate with disease activity (BVAS/WG; r = 0.09, p = 0.60). There were no statistically significant differences in the frequency of major clinical manifestations between patients with or without AECA. Conclusion. AECA, as measured using HUVEC, are not highly prevalent among patients with active WG, are not associated with specific clinical manifestations, and do not correlate with level of disease activity.

KW - Antiendothelial cell antibodies

KW - Disease activity measures

KW - Wegener's granulomatosis

UR - http://www.scopus.com/inward/record.url?scp=34248674363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248674363&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 1027

EP - 1031

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -